PRAX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PR

Mkt Cap

$6.75B

Volume

438.96K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Why Is Praxis Precision Stock Soaring Tuesday?Praxis Precision Medicines (NASDAQ: PRAX) shares surged 7.15% on Tuesday following FDA acceptance of its New Drug Application for ulixacaltamide, a treatment for essential tremor, with an FDA decision target date of January 29, 2027. The company also reported positive Phase 3 trial results and significant seizure reduction data from its elsunersen program. The stock is trading near its 52-week high with strong technical momentum and a Buy rating from analysts with a $588.60 average price target.Benzinga · Apr 14, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyPraxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients showed improvements in sleep, motor function, and attention, with no serious adverse events reported.GlobeNewswire Inc. · Apr 6, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterCormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.The Motley Fool · Mar 16, 2026

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its PipelineDeerfield Management Company increased its stake in Praxis Precision Medicines by 62,500 shares, bringing its total position to $266.25 million. PRAX stock has surged 685% over the past year, significantly outperforming the S&P 500. The biotech company recently submitted FDA applications for two drug candidates and has four leading programs that could represent over $20 billion in potential revenue if successfully commercialized. With $926 million in cash and a recent $621 million offering, Praxis is well-positioned financially through 2028.The Motley Fool · Mar 13, 2026

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA FilingsPraxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceeding $20 billion if approved, the company is positioned for significant growth, though regulatory approval remains a key risk.The Motley Fool · Mar 13, 2026

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 MillionPerceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares (worth ~$80.34 million) in Q4 2025, bringing its total position to $588.30 million and making it the fund's largest holding at 10.8% of AUM. The biotech company's stock has surged 320% over the past year as it advances toward commercialization with two FDA NDAs submitted and a strong cash position of $1.547 billion.The Motley Fool · Feb 22, 2026

Soleus Adds a Significant Number of Celcuity SharesSoleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.The Motley Fool · Feb 13, 2026

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive AppointmentsPraxis Precision Medicines announced strategic leadership changes to support its transition into late-stage development and commercial execution. The company appointed Jeffrey B. Kindler (former Pfizer CEO) and Stuart Arbuckle (former Vertex COO) to its board of directors, and promoted Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. These moves align with the company's focus on commercial launch planning, late-stage development, and strategic value optimization for its CNS disorder therapies.GlobeNewswire Inc. · Jan 8, 2026

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public OfferingPraxis Precision Medicines priced an underwritten public offering of 2.212 million shares at $260 per share, generating approximately $575 million in gross proceeds. The offering is expected to close on January 8, 2026, with underwriters granted a 30-day option to purchase an additional 331,800 shares. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder therapies.GlobeNewswire Inc. · Jan 7, 2026

Praxis Precision Medicines, Inc. Announces Proposed Public OfferingPraxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced a proposed public offering of common stock and pre-funded warrants. The offering is being managed by Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities as joint book-running managers, with completion subject to market conditions.Benzinga · Jan 6, 2026

PR

PRAXPraxis Precision Medicines, Inc. Common Stock

PRAX

Pay with—

Available Balance0.00

Your PositionYou don't own any PRAX yet.

Related Tickers

Earnings